Fermenta Board Approves Sale of Environmental Solutions Business to Wholly Owned Subsidiary

▴ Fermenta Biotech Limited
To enable specialized management and accelerated growth of environmental business vertical that includes waste management, water treatment, and bioremediation
Mumbai, 19 September 2025: Fermenta Biotech Limited, India's leading manufacturer of premium-grade APIs, intermediates, and nutritional premixes for the global markets, today announced that its Board of Directors has approved the sale of its environmental solutions business operations to a wholly owned subsidiary, Fermenta Environment Solutions Private Limited (FESPL) on a slump sale basis. This strategic business transfer, effective 1 October 2025, represents another important milestone in Fermenta's commitment to sustainable innovation and environmental stewardship and enhances operational focus both at parent and subsidiary level. Following this transfer the subsidiary will continue and expand the business of conceiving, designing, providing, and manufacturing for sale and distribution a wide range of environmental solutions. The subsidiary's comprehensive portfolio will include—but not be limited to—solid waste management, wastewater and water management, lake and pond bioremediation, fly ash handling, ground and soil remediation, oil sludge treatment, and air pollution management. Additionally, the entity will undertake the installation, operation, and maintenance of sewage treatment plants (STPs), water treatment plants (WTPs), and effluent treatment plants (ETPs), either independently or through strategic collaborations. This strategic move integrates scientific capability with sustainable development, positioning FESPL to address one of the most pressing challenges of our time—environmental resilience. The initiative also aligns with Fermenta’s vision to leverage its expertise and capabilities to create solutions that benefit both business and society. Comment from Prashant Nagre - Managing Director "The Board's approval for this slump sale transaction marks a significant step in our journey toward comprehensive sustainability leadership. By transferring our environmental solutions portfolio to a dedicated subsidiary, we are creating a focused entity that can accelerate growth and innovation in this critical sector. This structured approach will enable specialized management, enhanced operational efficiency, and targeted resource allocation at both parent and subsidiary levels. The transaction reflects Fermenta’s commitment to applying our decades-honed capabilities to address critical environmental challenges while creating long-term value for all stakeholders. This strategic move perfectly complements our core business and reinforces our strategy of sustainable innovation that benefits both business and society." About Fermenta Biotech Limited (www.fermentabiotech.com) delivers best-in-class, science-validated nutritional ingredients across pharmaceuticals, dietary supplements, food & beverage, veterinary, and animal nutrition industries. Our state-of-the-art manufacturing facilities located at Kullu (Himachal Pradesh), Dahej (Gujarat), and Tirupati (Andhra Pradesh), supported by the R&D Excellence Centre at Thane (near Mumbai) drive Fermenta's comprehensive portfolio of premium vitamins, nutritional premixes and ingredients that exceed the unique needs and stringent regulatory standards of over 400 discerning customers in more than 60 countries. With decades of expertise at global-scale complex manufacturing, Fermenta also provide research-based custom solutions in green chemistry, APIs & intermediates, and environmental solutions. Safe Harbour Statement Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, market opportunities, competitive positioning, slump sale transaction potential, the progress and results of research and development, potential project characteristics, project potential, and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements due to various factors including market conditions, regulatory changes, competitive dynamics, and other business risks. Fermenta Biotech Limited assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions, or other factors, except as and when required by applicable law.
Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026